Low‐dose nivolumab for extranodal natural killer/T‐cell lymphoma, nasal type
Satish Maharaj, Simone Chang · 2024
Read Low‐dose nivolumab for extranodal natural killer/T‐cell lymphoma, nasal type by Satish Maharaj, Simone Chang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11647695.txt.
Description
Satish Maharaj and Simone Chang published a case report in 2024 on a rare lymphoma and low-dose immune therapy. The cancer strikes natural killer and T cells, often in the nose, and carries poor odds. Checkpoint drugs that free the immune system have shown promise when the disease returns.
Their patient was a 59-year-old man whose left nasal airway was nearly blocked by a tumor. Scans showed a mass in the left nasal cavity, and surgery both debulked it and took tissue for testing. Stains and gene tests confirmed the nasal type of the lymphoma, with the Epstein-Barr virus present. Staging placed the disease at stage two, local to the nose area. The report frames low-dose treatment as an option worth study.
Catalog record
| CREATOR | Satish Maharaj, Simone Chang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |